View Author
patient myeloma thalidomide treatment bortezomib therapy study dexamethasone group combination response cancer regimen lenalidomide blood survival month neutropenia disease grade melphalan table chemotherapy trial university effect phase factor palumbo cycle hematology oncol prednisone randomized result pegylated liposomal doxorubicin hospital doxorubicin agent department signi ficantly signi progression enzastaurin outcome neuropathy erasmus mc lymphoma serum j clin oncol celgene guideline g-csf high-dose dexamethasone transplantation high-dose event ef ficacy infection criteria recommendation level cyclophosphamide reduction leukemia group guidelines erasmu imid-exposed maintenance days 1-4 response rate imid-naive volume comorbidity toxicity number ն 75 years increase janssen-cilag plasma
7 Most Recent Publications
|
How to manage neutropenia in multiple myeloma
(Article)
Palumbo, A. Bladé, J. Spencer, A. Sonneveld, P. San Miguel, J-F. Boccadoro, M. Palladino, C. Davies, F. Dimopoulos, M.A. Dmoszynska, A. Einsele, H. Moreau, P. Sezer, O. |
2012-02-01
|
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
(Article)
Palumbo, A. Bringhen, S. Zweegman, S. Terpos, E. Davies, F. Driessen, C. Gimsing, P. Gramatzki, M. Hajek, R. Johnsen, H.E. Da Costa, F.L. Sezer, O. Ludwig, H. Spencer, A. Beksaç, M. Morgan, G. Einsele, H. San Miguel, J. Sonneveld, P. Dimopoulos, M.A. Bladé, J. Mateos, M.V. Rosiñol, L. Boccadoro, M. Cavo, M. Lokhorst, H.M. |
2011-10-27
|
|
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
(Article)
Palumbo, A. Sezer, O. Kumar, S. Hajek, R. Giralt, S. Bringhen, S. Anderson, K.C. Richardson, P.G. Cavo, M. Davies, F. Bladé, J. Einsele, H. Kyle, R. Dimopoulos, M.A. Spencer, A. Dispenzieri, A. Reiman, T. Shimizu, K. Lee, J.H. Attal, M. Boccadoro, M. Mateos, M.V. Chen, W. Miguel, J.S. Ludwig, H. Joshua, D. Chim, J. Hungria, V. Turesson, I. Durie, B.G.M. Lonial, S. Orlowski, R.Z. Moreau, P. Niesvizky, R. Morgan, G. Comenzo, R.L. Sonneveld, P. |
2009-06-08
|
|
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment
(Article)
Bladé, J. Sonneveld, P. Harousseau, J-L. Orlowski, R.Z. San Miguel, J-F. Sutherland, H. Hajek, R. Nagler, A. Spencer, A. Robak, T. Cibeira, M.T. Zhuang, S.H. |
2008-12-01
|
|
Thalidomide for treatment of multiple myeloma: 10 years later
(Article)
Palumbo, A. Facon, T. Boccadoro, M. Harousseau, J-L. Sonneveld, P. Bladé, J. Offidani, M. Gay, F. Moreau, P. Waage, A. Spencer, A. Ludwig, H. |
2008-04-15
|
|
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
(Article)
Sonneveld, P. Hajek, R. Nagler, A. Spencer, A. Bladé, J. Robak, T. Zhuang, S.H. Harousseau, J-L. Orlowski, R.Z. |
2008-04-01
|
|
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma
(Article)
Morschhauser, F. Seymour, J.F. Cartron, G. Pezzutto, A. Spencer, A. Reyes, F. Dreyling, M. Kluin-Nelemans, H.C. Grigg, A. Wolf, M. Pfreundschuh, M. Tilly, H. Raemaekers, J. Veer, M.B. van 't Milpied, N. |
2008-02-01
|
